Skip Navigation



Nicotine & Tobacco Research Advance Access published online on March 8, 2009
Nicotine & Tobacco Research, doi:10.1093/ntr/ntp007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Article Summary
Right arrow All Versions of this Article:
11/4/404    most recent
ntp007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Munafò, M. R.
Right arrow Articles by Aveyard, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Munafò, M. R.
Right arrow Articles by Aveyard, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial

Marcus R. Munafò, Elaine C. Johnstone, Michael F. G. Murphy and Paul Aveyard

Marcus R. Munafò, Ph.D., Department of Experimental Psychology, University of Bristol, Bristol, UK
Elaine C. Johnstone, Ph.D., Department of Clinical Pharmacology, University of Oxford, Oxford, UK
Michael F. G. Murphy, M.D., Childhood Cancer Research Group, University of Oxford, Oxford, UK
Paul Aveyard, M.D., Ph.D., Department of Primary Care and General Practice, University of Birmingham, Birmingham, UK

Corresponding Author: Marcus R. Munafò, Ph.D., Department of Experimental Psychology, University of Bristol, 12a Priory Road, Bristol BS8 1TU, UK. Telephone: +44 (117) 9546841. Fax: +44 (117) 9288588. Email: marcus.munafo{at}bristol.ac.uk


  Abstract

Introduction: We previously reported evidence that the T allele of the dopamine type-2 receptor (DRD2) rs1800497 polymorphism is associated with improved response to nicotine replacement therapy (NRT) relative to placebo and that this association may only be present in females. However, evidence of the poor replication validity of genetic association studies is growing, particularly among those that report subgroup analyses. We therefore attempted to replicate our previous finding of an association between the DRD2 rs1800497 genotype and response to NRT in a new, larger cohort, with greater statistical power.

Methods: Participants were randomly assigned to one of two levels of smoking cessation behavioral support (usual care vs. weekly support). All participants received 8 weeks of 15-mg NRT transdermal patch.

Results: The presence of one or more T alleles was associated with a slightly but not significantly lower likelihood of abstinence at 3 and 6 months. We found evidence of a genotype x sex interaction effect. However, stratified analyses indicated a main effect of genotype opposite to the effect reported previously, with females carrying one or more copies of the T allele less likely to be abstinent.

Discussion: Our results do not support an association between the DRD2 rs1800497 (Taq1A) polymorphism and response to NRT, contrary to our previous study.

Received: April 22, 2008; Accepted: July 18, 2008
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.